TUMOR MUTATION
BURDEN (TMB)
TMB identifies patients who may benefit from checkpoint inhibitors based on a different biological mechanism than PD-L1 or MSI. When those two are negative, TMB is often the third marker checked -- and can open a tumour-agnostic immunotherapy approval.
TMB at a Glance
- >=10Mutations per megabase: FDA threshold for tumour-agnostic pembrolizumab approval
- 2020Year of FDA tumour-agnostic pembrolizumab approval for TMB-high tumours
- 3rdImmunotherapy biomarker to check after PD-L1 and MSI are both negative
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Your TMB Score and Immunotherapy Eligibility?
CancerFax reviews your NGS results including TMB and MSI status to assess immunotherapy eligibility across all relevant biomarker pathways.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.